Research graph
References from Targeting KRAS-Mutant Lung Cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
KRAS mutations in advanced non-small cell lung cancer: from biology to novel therapeutic strategies
2025 · External reference
KRAS mutation: from undruggable to druggable in cancer
2021 · External reference
A structural model of a Ras-Raf signalosome
2021 · External reference
Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties
2024 · External reference
Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer
2022 · External reference
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities
2015 · External reference
Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
2022 · External reference
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
2019 · External reference
Sotorasib for lung cancers with KRAS p.G12C mutation
2021 · External reference
Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation
2022 · External reference
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
2025 · External reference
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
2023 · External reference
Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation
2023 · External reference
MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): results from KANDLELIT-001
2025 · External reference
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
2025 · External reference
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: first-in-human phase I study
2024 · External reference
D-1553 (garsorasib), a potent and selective inhibitor of KRASG12C in patients with NSCLC: phase 1 study results
2023 · External reference
First-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: updated efficacy and safety from KROCUS study
2025 · External reference
Acquired resistance in cancer: towards targeted therapeutic strategies
2025 · External reference
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
2025 · External reference
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
2024 · External reference
Acquired resistance to KRASG12C inhibition in cancer
2021 · External reference
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
2025 · External reference
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
2023 · External reference
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
2024 · External reference
Response and resistance to RAS inhibition in cancer
2025 · External reference
Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant non–small cell lung cancer
2024 · External reference
Targeting KRAS in cancer
2024 · External reference
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
2023 · External reference
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
2023 · External reference
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
2024 · External reference
A pan-RAS inhibitor with a unique mechanism of action blocks tumor growth and induces antitumor immunity in gastrointestinal cancer
2025 · External reference
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
2024 · External reference
AN9025, an orally bioavailable pan-RAS(ON) inhibitor with potent, broad-spectrum anti-tumor activity
2025 · External reference
GFH276: a molecular glue panRAS(on) inhibitor with broad spectrum anti-tumor activities
2025 · External reference
Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
2023 · External reference
Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
2025 · External reference
Mechanisms of resistance to active state selective tri-complex RAS inhibitors
External reference
Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies
2025 · External reference
Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment
2023 · External reference
Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C
2025 · External reference
Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER)
2024 · External reference
FMC-376, a dual inhibitor of ON + OFF states of KRAS G12C, is active in sotorasib resistant PDX models
2025 · External reference
Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors
2025 · External reference
Setidegrasib in advanced non–small-cell lung cancer and pancreatic cancer
2026 · External reference
A first-in-class EGFR-directed KRAS G12V selective inhibitor
2025 · External reference
RMC-5127, a first-in-class, orally bioavailable mutant-selective RASG12V(ON) inhibitor is central nervous system (CNS)-penetrant and demonstrates anti-tumor activity in a preclinical intracranial xenograft model
2024 · External reference
QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity
2025 · External reference
KRAS inhibitors: resistance drivers and combinatorial strategies
2025 · External reference
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
2021 · External reference
Glecirasib, a potent and selective covalent KRAS G12C inhibitor exhibiting synergism with cetuximab or SHP2 inhibitor JAB-3312
2025 · External reference
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
2026 · External reference
Immune modulatory effects of oncogenic KRAS in cancer
2020 · External reference
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
2025 · External reference
CodeBreaK 100/101: first report of safety/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC
2022 · External reference
Toxicity from sotorasib after immune checkpoint inhibitors: a note of caution and reflections of future advancements in the field
2023 · External reference
First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study
2025 · External reference
Efficacy and safety of olomorasib in combination with pembrolizumab in treatment of patients with KRAS G12C-mutant advanced NSCLC
2026 · External reference
A single-arm phase 2 study of sotorasib plus carboplatin and pemetrexed in patients with advanced nonsquamous NSCLC with KRAS G12C mutation (WJOG14821L, SCARLET)
2025 · External reference
Roles and inhibitors of FAK in cancer: current advances and future directions
2024 · External reference
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
2020 · External reference
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial
2025 · External reference
Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery
2025 · External reference
Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy
2025 · External reference
KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
2023 · External reference
P3.18.40 KRAS peptide vaccine combined with chemotherapy, nivolumab and ipilimumab in advanced KRAS mutated non-small cell lung cancer
2025 · External reference
